Xu-Monette, Z. Y., Luo, C., Yu, L., Li, Y., Bhagat, G., Tzankov, A., Visco, C., Fan, X., Dybkaer, K., Sakhdari, A., Wang, N. T., Yuan, A. F., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Perry, A. M., Song, W., O’Malley, D., … Young, K. H. (2024). DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2024.2384667

Scuoppo, C., Cai, B., Ofori, K., Scholze, H., Kumar, R., D’Alessandro, A., Basso, K., Pasqualucci, L., & Dalla-Favera, R. (2024). Repurposing NAMPT Inhibitors for Germinal Center B Cell–Like Diffuse Large B-Cell Lymphoma. Blood Cancer Discovery, 5(6), 417–427. https://doi.org/10.1158/2643-3230.bcd-24-0020

Cherng, H.-J. J., & Herrera, A. (2024). Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside? Current Treatment Options in Oncology, 25(5), 659–678. https://doi.org/10.1007/s11864-024-01201-8

Xu-Monette, Z. Y., Li, Y., Snyder, T., Yu, T., Lu, T., Tzankov, A., Visco, C., Bhagat, G., Qian, W., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Wang, Y., Go, H., Ponzoni, M., Ferreri, A. J. M., … Young, K. H. (2023). Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clinical Cancer Research, 29(23), 4808–4821. https://doi.org/10.1158/1078-0432.ccr-23-1554

Zhou, N., Choi, J., Grothusen, G., Kim, B.-J., Ren, D., Cao, Z., Liu, Y., Li, Q., Inamdar, A., Beer, T., Tang, H.-Y., Perkey, E., Maillard, I., Bonasio, R., Shi, J., Ruella, M., Wan, L., & Busino, L. (2023). DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood, 142(11), 973–988. https://doi.org/10.1182/blood.2022018752

Cherng, H.-J. J., Alig, S. K., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., Turturro, F., Hagemeister, F., Craig, A. F. M., Macaulay, C. W., Rodriguez, M. A., Lee, H. J., McDonnell, T. J., Flowers, C. R., Vega, F., Green, M. R., Feng, L., Kurtz, D. M., Alizadeh, A. A., … Westin, J. R. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 7(7), 1137–1145. https://doi.org/10.1182/bloodadvances.2022008174

Torka, P., Pederson, L. D., Knopp, M. V., Poon, D., Zhang, J., Kahl, B. S., Higley, H. R., Kelloff, G., Friedberg, J. W., Schwartz, L. H., Wilson, W. H., Leonard, J. P., Bartlett, N. L., Schöder, H., & Ruppert, A. S. (2023). Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis. Cancer Medicine, 12(7), 8211–8217. Portico. https://doi.org/10.1002/cam4.5628

Vlasevska, S., Garcia-Ibanez, L., Duval, R., Holmes, A. B., Jahan, R., Cai, B., Kim, A., Mo, T., Basso, K., Soni, R. K., Bhagat, G., Dalla-Favera, R., & Pasqualucci, L. (2023). KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells. Proceedings of the National Academy of Sciences, 120(11). https://doi.org/10.1073/pnas.2218330120

Afify, Z. A. M., Taj, M. M., Orjuela‐Grimm, M., Srivatsa, K., Miller, T. P., Edington, H. J., Dalal, M., Robles, J., Ford, J. B., Ehrhardt, M. J., Ureda, T. J., Rubinstein, J. D., McCormack, S., Rivers, J. M., Chisholm, K. M., Kavanaugh, M. K., Bukowinski, A. J., Friehling, E. D., Ford, M. C., … Mason, C. C. (2022). Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders. Cancer, 129(5), 780–789. Portico. https://doi.org/10.1002/cncr.34600

Cherng, H. J., Xu, G., Feng, L., Steiner, R., Fayad, L., Strati, P., Nair, R., Nastoupil, L. J., Lee, H. J., Neelapu, S. S., Flowers, C. R., Rodriguez, M., Wang, M., Hagemeister, F., Pinnix, C. C., Ramdial, J., Srour, S., Nieto, Y., Rezvani, K., … Ahmed, S. (2022). Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant. British Journal of Haematology, 200(1), 35–44. Portico. https://doi.org/10.1111/bjh.18441

Yuen, C. A., Hsu, J.-M., Van Besien, K., Reshef, R., Iwamoto, F. M., Haggiagi, A., Liechty, B., Zhang, C., Wesley, S. F., & Magge, R. (2022). Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. Journal of Immunotherapy, 45(5), 254–262. https://doi.org/10.1097/cji.0000000000000416

Xu-Monette, Z. Y., Wei, L., Fang, X., Au, Q., Nunns, H., Nagy, M., Tzankov, A., Zhu, F., Visco, C., Bhagat, G., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Sun, X., Han, X., Go, H., … Young, K. H. (2022). Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 28(5), 972–983. https://doi.org/10.1158/1078-0432.ccr-21-2949

Albitar, M., Zhang, H., Goy, A., Xu-Monette, Z. Y., Bhagat, G., Visco, C., Tzankov, A., Fang, X., Zhu, F., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Huh, J., Ponzoni, M., Ferreri, A. J. M., Møller, M. B., … Young, K. H. (2022). Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer Journal, 12(2). https://doi.org/10.1038/s41408-022-00617-5